E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases

Srinivas K, Lakshmi Sowjanya S, Shama K.

Abstract
Background: Hypertension is a global health epidemic, and blood uric acid levels are a major risk factor for the development of cardiovascular and renal problems. Serum uric acid levels may be reduced as a result of treatment, which may reduce cardiovascular risk factors. Losartan has a pleiotropic uricosuric effect that lowers the risk of future cardiovascular problems.

Aims and Objectives: To study and evaluate how losartan affected serum uric acid levels in people with essential hypertension.

Materials and Methods: A source of 120 newly diagnosed participants with stage 1 and stage 2 essential hypertension aged between 31 and 65 years, both genders, with elevated serum uric acid levels, were recruited. All participants were medicated with Tablet Losartan 50 mg once daily during the morning session for 1 month. The changes in the serum uric acid levels and blood pressure at baseline, 1 month, 3 months, and 6 months were measured and analyzed.

Results: Stage-2 hypertension (53.3%) was common, followed by stage-3 (37.5%) and stage-1 hypertension (9.17%). The mean levels and mean reduction of systolic blood pressure, diastolic blood pressure, and serum uric acid levels were statistically significant (P < 0.05). Adverse drug reactions such as headache were observed in 2.5% of cases, dizziness in 1.67%, and mild hypotension in 0.83% of cases.

Conclusion: Losartan therapy for 6 months can effectively decrease the serum uric acid and blood pressure in patients with essential hypertension.

Key words: Essential Hypertension; Losartan; Blood Pressure; Serum Uric Acid


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Srinivas K
Articles by Lakshmi Sowjanya S
Articles by Shama K
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

K S, S LS, K S. Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. Natl J Physiol Pharm Pharmacol. 2024; 14(2): 344-347. doi:10.5455/njppp.2023.13.07362202326072023


Web Style

K S, S LS, K S. Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. https://www.njppp.com/?mno=161856 [Access: January 31, 2024]. doi:10.5455/njppp.2023.13.07362202326072023


AMA (American Medical Association) Style

K S, S LS, K S. Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. Natl J Physiol Pharm Pharmacol. 2024; 14(2): 344-347. doi:10.5455/njppp.2023.13.07362202326072023



Vancouver/ICMJE Style

K S, S LS, K S. Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. Natl J Physiol Pharm Pharmacol. (2024), [cited January 31, 2024]; 14(2): 344-347. doi:10.5455/njppp.2023.13.07362202326072023



Harvard Style

K, S., S, . L. S. & K, . S. (2024) Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. Natl J Physiol Pharm Pharmacol, 14 (2), 344-347. doi:10.5455/njppp.2023.13.07362202326072023



Turabian Style

K, Srinivas, Lakshmi Sowjanya S, and Shama K. 2024. Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. National Journal of Physiology, Pharmacy and Pharmacology, 14 (2), 344-347. doi:10.5455/njppp.2023.13.07362202326072023



Chicago Style

K, Srinivas, Lakshmi Sowjanya S, and Shama K. "Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 344-347. doi:10.5455/njppp.2023.13.07362202326072023



MLA (The Modern Language Association) Style

K, Srinivas, Lakshmi Sowjanya S, and Shama K. "Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases." National Journal of Physiology, Pharmacy and Pharmacology 14.2 (2024), 344-347. Print. doi:10.5455/njppp.2023.13.07362202326072023



APA (American Psychological Association) Style

K, S., S, . L. S. & K, . S. (2024) Angiotensin-II receptor antagonist losartan on serum uric acid levels in essential hypertension cases. National Journal of Physiology, Pharmacy and Pharmacology, 14 (2), 344-347. doi:10.5455/njppp.2023.13.07362202326072023